Management of therapy-resistant systemic lupus erythematosus with rituximab: Report of a case and review of the literature

Acta Clinica Belgica

Volumn 60, Issue 2, 2005, Pages 102-105

  Van Den Bergh, B ^a   Selleslag, D ^a   Boelaert, J R ^a   Matthys, E G ^a   Schurgers, M ^a   Vandecasteele, S ^a   De Vriese, An S ^a  

^a General Hospital St Jan   (Belgium)

Author keywords

Rituximab; Systemic lupus erythematosus; Therapy resistant

Indexed keywords

CYTOTOXIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; NEPHRITIS; PLASMAPHERESIS; PNEUMONIA; PROGNOSIS; RELAPSE; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK ASSESSMENT; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 24044480949     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2005.019     Document Type: Article

References (19)

1. Flanc RS, Roberts MA, Strippoli GF, Chadban S, Kerr P, Atkins R. Treatment of diffuse proliferative lupus nephritis: a metaanalysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 383-5.
2. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-80.
3. Chan T, Li F, Tang C et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-62.
4. Lewis E, Hunsicker L, Lan S, Rohde R, Lachin J. A controlled trial of plasmapheresis therapy during severe lupus nephritis. N Engl J Med 1992; 326: 1373-9.
5. Boletis J, Ionnidis J, Boli K, Moutsopoulos H. Intravenous immunoglobulin compares with cyclophosphamide for proliferative lupus nephritis. Lancet 1999; 354: 569-70.
6. Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment of lupus nephritis. Arthritis Rheum 2000; 29: 321-7.
7. Dooley M, Cosio F, Nachman P, Falkenhain M, Hogan S, Falk R, Hebert L. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-9.
8. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998; 32: 318-22.
9. Cohen Y, Polliack A, Nagler A. Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support. Curr Pharm Des 2003; 9: 279-88.
10. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune disease. Curr Opin Pharmacol 2004; 4 (4): 398-402.
11. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody. Ann Oncol 2003; 14: 520-35.
12. Edwards J, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
13. Tsokos G. B cells, Be gone_ B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med 2004; 350: 2546-8.
14. Weide R, Heymanns J, Pandorf A, Köppler H. Succesful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003; 12: 779-82.
15. Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12: 783-7.
16. Leandro M, Edwards J, Cambridge G, Ehrenstein M, Isenberg D. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-7.
17. Leandro M, Ehrenstein M, Edwards J, et al. Teatment of refractory lupus nephritis with B lymphocytedepletion. Arthritis Rheum 2003; 48: S 378.
18. Looney J, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16: 180-5.
19. Looney R., Anolik J., Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 2004; 13: 381-90.